Compare SEE & CRSP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SEE | CRSP |
|---|---|---|
| Founded | 1960 | 2013 |
| Country | United States | Switzerland |
| Employees | N/A | N/A |
| Industry | Major Chemicals | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.1B | 5.6B |
| IPO Year | N/A | 2016 |
| Metric | SEE | CRSP |
|---|---|---|
| Price | $42.05 | $58.13 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 11 | 19 |
| Target Price | $43.45 | ★ $71.50 |
| AVG Volume (30 Days) | ★ 3.4M | 2.5M |
| Earning Date | 11-04-2025 | 11-10-2025 |
| Dividend Yield | ★ 1.89% | N/A |
| EPS Growth | ★ 13.73 | N/A |
| EPS | ★ 3.09 | N/A |
| Revenue | ★ $5,331,600,000.00 | $38,337,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $1.16 | $723.84 |
| P/E Ratio | $13.67 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $22.78 | $30.04 |
| 52 Week High | $44.27 | $78.48 |
| Indicator | SEE | CRSP |
|---|---|---|
| Relative Strength Index (RSI) | 60.99 | 55.81 |
| Support Level | $42.44 | $51.16 |
| Resistance Level | $43.27 | $59.77 |
| Average True Range (ATR) | 0.65 | 3.19 |
| MACD | -0.26 | 1.15 |
| Stochastic Oscillator | 11.73 | 90.72 |
Sealed Air is organized via two reporting segments. Food includes food packaging products like Cryovac, Darfresh, and OptiDure aimed primarily at meats. Protective includes Sealed Air's Bubble Wrap, Instapak, Jiffy mailers, and shrink film packaging systems that cater to industrial and e-commerce applications.
Crispr Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for clustered regularly interspaced short palindromic repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. Crispr's first approved drug is Casgevy, which was developed in collaboration with Vertex Pharmaceuticals and targets sickle-cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is advancing a variety of gene editing programs in immuno-oncology, cardiovascular, and a stem cell-derived therapy to treat Type 1 diabetes.